Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Sees Large Growth in Short Interest

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,132 shares, an increase of 3,395.1% from the March 31st total of 61 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily volume of 8,439 shares, the short-interest ratio is currently 0.3 days.

Bitwise MARA Option Income Strategy ETF Price Performance

Shares of Bitwise MARA Option Income Strategy ETF stock traded down $0.18 during trading on Friday, hitting $15.62. 1,776 shares of the stock were exchanged, compared to its average volume of 5,904. Bitwise MARA Option Income Strategy ETF has a 12-month low of $11.99 and a 12-month high of $60.73. The stock has a market cap of $2.97 million, a price-to-earnings ratio of 312.40 and a beta of 3.78. The firm’s 50-day moving average price is $14.05 and its 200 day moving average price is $19.51.

Insider Activity

In other news, insider Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction on Friday, April 17th. The shares were sold at an average price of $47.67, for a total transaction of $238,350.00. Following the completion of the sale, the insider directly owned 25,000 shares of the company’s stock, valued at approximately $1,191,750. The trade was a 16.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 50,000 shares of company stock worth $1,781,150. 37.30% of the stock is currently owned by insiders.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.